Analyze up to 5000 proteins with just 2μL of sample
Discover novel biological insights by analyzing 1000s of proteins with High-Plex technologies powered by NGS!
How will High-Plex proteomics take your research to the next level?
Traditional targeted protein analysis approaches like multiplex assays are valuable for enhancing our understanding of specific pathways and biomarker behavior but lack potential for proteome-wide discoveries and screening.
High-plex analysis leaves behind the limitations of traditional approaches. Incorporate High-plex analysis into your research methodology to unlock novel biological insights.
What is High-Plex Protein Analysis?
High-Plex Protein Analysis refers to the simultaneous analysis of 100s to 1000s of proteins providing a comprehensive view of the protein landscape.
The emergence of oligonucleotide-labeling of antibodies has enabled NGS technologies to be used in protein research and led to new levels of multiplexing.
The new High-Plex Protein technologies based on NGS have allowed unprecedented quality, speed, sensitivity, specificity, and proteome coverage.
You can now discover important biological mechanisms and focus on novel biological insights.
Why invest in a High-Plex protein analysis?
Take your research to the next level
Deep Biological Insights:
Get a comprehensive view of the protein landscape and reveal protein mechanisms and new biological insights.
Identify new proteins for early disease detection, prognosis, or prediction of treatment options.
Cost-Effectiveness in focused panels:
Design new focused panels with the truly important proteins of interest.
Drug Development and Validation:
Identify proteins affected by drugs or validate drug effects on multiple proteins.
Profile individual patients’ protein expression patterns that guide treatment decisions and predict responses to specific interventions.
High-Plex studies often generate comprehensive datasets that can lead to impactful publications, advancing the field and contributing to scientific knowledge.
In research and pharmaceutical industries, staying at the forefront of technology can provide a competitive advantage. High-Plex analysis allows you to harness cutting-edge tools to answer complex research questions.
What does High-Plex measure?
Our High-Plex panels, powered by Olink’s PEA technology, offer unparalleled specificity and scale to meet diverse research needs. Choose from a wide selection of curated panels for specific research areas or select more comprehensive solutions to explore broad biomarker screening.
Panels by research area
Focus on specialized research areas with OLink’s 384-target panels, designed for maximal relevance and impact. Each research area has two distinct 384-panels to ensure a comprehensive analysis.
High-Plex Cardiometabolic I/II:
Two dedicated 384-panels for cardiovascular and metabolic studies.
High-Plex Inflammation I/II:
Two dedicated 384-panels for proteins associated with inflammatory and immune response functions.
High-Plex Neurology I/II: Two highly-specific 384-panels for neurology and neurological diseases.
High-Plex Oncology I/II: Two high-performance 384-panels for proteins involved in major cancer pathways.
Broad Biomarker Screening Panels
Measure either 3072 or 5300 targets to answer a variety of research questions and cover the majority of key biological pathways.
High-Plex Explore: Combines all 8 research-specific panels into one, allowing for the simultaneous analysis of 3,072 targets.
Measure up to 5,300 targets in one assay for the most comprehensive proteomic analysis available.
How we work
Design the study
Instead of just analyzing your samples, we provide you with a dedicated proteomic specialist who possesses extensive knowledge and ensures that the study design is tailored to your specific requirements and hypothesis.
Send your samples to either our European or US dedicated sample collection sites, equipped with state-of-the-art storage infrastructure and monitoring. You can use either our approved carriers or follow your own shipment processes.
Obtain a comprehensive proteomic analysis report encompassing the study design, detailed methodology, dataset, visualizations, bioinformatic analysis, and any additional agreed-upon services outlined in the study plan.
Schedule a one-hour consultation call with our Chief Scientific Officer and our Project Manager to discuss crucial biological discoveries and address any further inquiries you may have for advancing your research to the next level.
20+ years of multiplex proteomics experience
GMP, ISO:9001, ISO:13485 compliant processes
Advanced bioinformatic analysis for proteomics
Orthogonal biomarker validation with multiple platforms
PhD, Acting CEO, Professor, National Technical University of Athens
Leonidas is one of the pioneers of multiplex assays & systems biology with more than 20 years of experience in the field of proteomics. He has studied at Duke, MIT and Harvard and is currently a professor at National Technical University of Athens. Leonidas co-founded Protavio in 2011 with the ultimate goal of improving people’s health through innovation in proteomics.
Co-founder, COO & Quality Director, MSc, MBA
Sophia holds an MSc in Robotics & Automation and an MBA from National Technical University of Athens. Her passion for engineering and entrepreneurship led her to co-found Protavio in 2011. Since 2018, she has held the position of Chief Operating Officer and Quality Director. Her decade long experience of business development and administration make her a key decision maker in Protavio.
Chief Scientific Officer, Phd
Nikos holds a PhD from Imperial College London and has over 15 years of work experience in academic and industrial research positions in the field of proteomics. Nikos joined Protavio in 2017 as a Quality Assurance & Project Manager. Since 2023, he holds the position of Chief Scientific Officer to advance Protavio’s proteomic solutions.
Chief Innovation Officer, Phd
Christos holds a PhD in AI & Bioinformatics from National Technical University of Athens and has extensive experience in creating and managing R&D projects and consortia. Christos joined Protavio in 2021 as a Research & Innovation manager. Since 2023, he holds the position of Chief Innovation Officer to drive new innovative projects using proteomics.